minutes was associated with an increased risk of stroke. 5 The TRENDS study (A Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics), in which nearly half of the patients had a history of clinical AF before study enrollment, found that patients with moderate stroke risk and AHREs ≥5.5 h/d in a 30-day period appeared to have double the thromboembolic risk. 6 The ASSERT study (Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial) in hypertensive patients found that episodes of AF lasting >6 minutes, compared with no episodes, were associated with a 2.5-fold risk of ischemic stroke or systemic embolism. 15 Then, the Detection of AHREs by Continuous Home Monitoring study in patients with heart failure found that, compared with patients without detected AHREs, patients with detected AHREs >3.8 h/d were 9 times more likely to develop a thromboembolism. 16 Most recently, a revisit of the ASSERT study data examined the duration of device-detected SCAF and the occurrence of stroke. Those investigators found that the risk of ischemic stroke or systemic embolism in patients with SCAF duration between 6 minutes and 24 hours was not significantly different from that in patients without SCAF. Only SCAF >24 hours was associated with an increased risk of ischemic stroke or systemic embolism. 17 It was concluded that SCAF >24 hours was associated with an increased risk of ischemic stroke or systemic embolism. And despite all of the above, there is the recognition that short AHREs are sometimes/often only a prelude to longer episodes, most recently reported by the RATEF Registry study (Registry of Atrial Tachycardia and Atrial Fibrillation Episodes). 7 Another puzzle is that asymptomatic episodes of SCAF detected by continuous monitoring in many, if not most, studies seem not to correlate closely with the timing of stroke. 4, [6] [7] [8] 15 It may be that AF and thrombus formation might occur some days, weeks, or even months before the clot dislodges from the atrium and causes an embolic stroke, but it is difficult to incriminate AF as the stroke mechanism when the AF occurs only after the stroke. In addition, there are many causes of ischemic stroke other than AF, none of which is unlikely in patients with AF. However, 1 large study, 18 which combined a clinical database and a data-monitoring database, clearly demonstrated that there was a much higher likelihood of finding AF ≥5.5 hours' duration within the days preceding the stroke than at other times.
If we accept that episodes of AHREs or SCAFs revealed by monitoring increase the risk of stroke and may be mechanistically involved, the next question is whether these embolic events occur frequently enough and long enough to justify attempting stroke prevention with anticoagulant therapy. For all the above studies, the absolute risk of stroke was much lower than expected. 19 For instance, in the relatively longer ASSERT study (mean follow-up, 3 years), the percentage of patients with a thromboembolic event was 1.20%, and the percentage of patients with AF detected before their thromboembolic event was 0.70%. Modeling studies have concluded that ischemic event rates of ≥0.9%/y (direct oral anticoagulants) and 1.7%/y (vitamin K antagonist therapy) are needed to justify anticoagulation for AF because of the major bleeding associated with anticoagulant therapy. 20 It is therefore far from clear that anticoagulation is justified, especially for episodes of AF <24 hours in duration.
Two randomized controlled trials are currently underway to explore this issue. ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With DeviceDetected Sub-Clinical Atrial Fibrillation; unique identifier: NCT01938248) 21 randomizes apixaban against aspirin in patients with AHREs, and in NOAH (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes; unique identifier: NCT02618577), 22 similar patients receive edoxaban or placebo, with blind aspirin treatment available for patients receiving placebo with an indication for aspirin. Neither trial will report for some years, which leaves the clinician still uncertain as to how to manage these patients. 23 European guidelines have strongly recommend using the discovery of AHREs to perform "further ECG monitoring to document AF before initiating AF therapy" unless the thrombogenic risk of the patient or patient preference warrants anticoagulation. 23 How does the REHEARSE-AF study help? Halcox and colleagues used biweekly, short recordings to identify AF in patients at risk of thrombogenesis. Is using intermittent, short iECG recordings rather than implantable device monitoring a "poor man's" version of arrhythmia monitoring? Certainly, the frequent iECG recording, well outside the clinical norm, will tend to reveal infrequent arrhythmia, but the short recording period gives little idea of the duration of the arrhythmia, and mere identification is not enough. Finally, the results of the REHEARSE-AF study also serve to focus on issues seen in virtually all the previous AHRE studies. First, the adverse event rate (stroke and systemic embolism) in the 1001 participants was quite low (0.02%). Second, of the 16 total strokes, 14 were either causally unrelated to AF or of undetermined origin.
As far as choosing whether to anticoagulate the patient, we might as well follow the advice of Yogi Berra: "When you come to a fork in the road [ 
